文献速递肝病消化道肿瘤与早癌

直接抗病毒药物治疗丙型肝炎后肝细胞癌风险:系统评价、Meta分析与Meta回归

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
PubMed 文献 · J Hepatol · 2017-08-09

该系统评价纳入41项研究(n=13,875例患者),比较直接抗病毒药物(DAA)与干扰素(IFN)方案治愈后肝细胞癌(HCC)的发生率和复发率。DAA研究随访更短且患者年龄更大。校正随访和年龄后,DAA治疗与HCC发生(RR 0.68;95%CI 0.18-2.55;p=0.55)或复发(RR 0.62;95%CI 0.11-3.45;p=0.56)风险升高无关。

要点

  • DAA与IFN治愈后HCC发生率分别为2.96/100人年与1.14/100人年。
  • DAA与IFN治愈后HCC复发率分别为12.16/100人年与9.21/100人年。
  • 校正随访和年龄后,DAA与HCC发生或复发风险升高无关。

核心结论

  • 没有证据表明DAA与IFN方案获得持续病毒学应答后HCC发生或复发风险存在差异。

研究设计与样本

  • 系统评价、Meta分析与Meta回归,检索2000年1月至2017年2月发表的报告。
  • 纳入41项研究(n=13,875例患者),其中26项评估HCC发生(IFN=17,DAA=9;前瞻性=19,回顾性=5,回顾-前瞻性=2),17项评估HCC复发(IFN=7,DAA=10;前瞻性=11,回顾性=5,回顾-前瞻性=1)。
  • 纳入标准为评估HCV治疗类型和应答与HCC结局关系的研究。
  • 采用随机效应Meta分析计算持续病毒学应答患者HCC发生率的合并估计值(每100人年)。

主要发现

  • 在评估HCC发生的研究中,DAA研究平均随访更短(1.0年 vs 5.5年),平均年龄更大(60岁 vs 52岁)。
  • 在评估HCC复发的研究中,DAA研究平均随访更短(1.3年 vs 5.0年),平均年龄相似(64岁 vs 66岁)。
  • IFN研究HCC发生率为1.14/100人年(95%CI 0.86-1.52),DAA研究为2.96/100人年(95%CI 1.76-4.96)。
  • IFN研究HCC复发率为9.21/100人年(95%CI 7.18-11.81),DAA研究为12.16/100人年(95%CI 5.00-29.58)。
  • 校正研究随访和年龄的Meta回归显示,DAA治疗与HCC发生风险升高无关(RR 0.68;95%CI 0.18-2.55;p=0.55),与HCC复发风险升高无关(RR 0.62;95%CI 0.11-3.45;p=0.56)。

关键数值与推荐

  • HCC发生率:IFN研究1.14/100人年(95%CI 0.86-1.52),DAA研究2.96/100人年(95%CI 1.76-4.96)。
  • HCC复发率:IFN研究9.21/100人年(95%CI 7.18-11.81),DAA研究12.16/100人年(95%CI 5.00-29.58)。
  • 校正随访和年龄后,DAA vs IFN的HCC发生风险RR 0.68(95%CI 0.18-2.55;p=0.55),HCC复发风险RR 0.62(95%CI 0.11-3.45;p=0.56)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The risk of hepatocellular carcinoma (HCC) occurrence or recurrence following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. The aims of this study were to compare the rate of HCC occurrence in patients with HCV-related cirrhosis, following DAA vs. interferon (IFN)-based cure, and to compare the rate of HCC recurrence in patients who received curative HCC treatment, following DAA vs. IFN-based cure. METHODS: A search was conducted for reports published between January 2000 and February 2017. Studies were included if they assessed HCC outcomes by type and response to HCV therapy. Random-effects meta-analyses were undertaken to determine a combined estimate of HCC incidence rate per 100/person-years (py) among patients with a sustained virological response (SVR). RESULTS: A total of 41 studies (n=13,875 patients), including 26 on HCC occurrence (IFN=17, DAA=9; prospective=19, retrospective=5, retrospective-prospective=2), and 17 on HCC recurrence (IFN=7, DAA=10; prospective=11, retrospective=5 and retrospective-prospective=1) were included. In studies assessing HCC occurrence, average follow-up was shorter (1.0 vs. 5.5years), and average age older (60 vs. 52years) in DAA studies. In studies assessing HCC recurrence, average follow-up was shorter (1.3 vs. 5.0years), but average age similar (64 vs. 66years) in DAA studies. HCC occurrence was 1.14/100 py (95% CI 0.86-1.52) and 2.96/100 py (95% CI 1.76-4.96) in IFN and DAA studies respectively. HCC recurrence was 9.21/100 py (95% CI 7.18-11.81) and 12.16/100 py (95% CI 5.00-29.58) in IFN and DAA studies respectively. In meta-regression adjusting for study follow-up and age, DAA therapy was not associated with higher HCC occurrence (RR 0.68; 95% CI 0.18-2.55; p=0.55) or recurrence (RR 0.62, 95% CI 0.11-3.45, p=0.56). CONCLUSION: There is no evidence for differential HCC occurrence or recurrence risk following SVR from DAA and IFN-based therapy. LAY SUMMARY: The risk of hepatocellular carcinoma (HCC) occurrence or recurrence following direct-acting antiviral (DAA) hepatitis C virus (HCV) therapy remains unclear. We conducted a meta-analysis to compare occurrence and recurrence of HCC in patients receiving either DAA or interferon (IFN) therapy. There is no evidence that HCC occurrence or recurrence is different between patients receiving DAA or IFN therapy.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017. PMID: 28802876. doi:10.1016/j.jhep.2017.07.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。